Clark Pharma Limited - Period Ending 2022-06-30

Clark Pharma Limited - Period Ending 2022-06-30


Clark Pharma Limited 10710051 false 2021-07-01 2022-06-30 2022-06-30 The principal activity of the company is that of a holding company. Digita Accounts Production Advanced 6.30.9574.0 true false true false 10710051 2021-07-01 2022-06-30 10710051 2022-06-30 10710051 bus:Director1 1 2022-06-30 10710051 core:RetainedEarningsAccumulatedLosses 2022-06-30 10710051 core:ShareCapital 2022-06-30 10710051 core:CurrentFinancialInstruments 2022-06-30 10710051 core:CurrentFinancialInstruments core:WithinOneYear 2022-06-30 10710051 core:Non-currentFinancialInstruments core:AfterOneYear 2022-06-30 10710051 core:OfficeEquipment 2022-06-30 10710051 bus:SmallEntities 2021-07-01 2022-06-30 10710051 bus:AuditExemptWithAccountantsReport 2021-07-01 2022-06-30 10710051 bus:FullAccounts 2021-07-01 2022-06-30 10710051 bus:SmallCompaniesRegimeForAccounts 2021-07-01 2022-06-30 10710051 bus:RegisteredOffice 2021-07-01 2022-06-30 10710051 bus:Director1 2021-07-01 2022-06-30 10710051 bus:Director1 1 2021-07-01 2022-06-30 10710051 bus:Director2 2021-07-01 2022-06-30 10710051 bus:PrivateLimitedCompanyLtd 2021-07-01 2022-06-30 10710051 core:OfficeEquipment 2021-07-01 2022-06-30 10710051 core:AllSubsidiaries 2021-07-01 2022-06-30 10710051 core:Subsidiary1 2021-07-01 2022-06-30 10710051 1 2021-07-01 2022-06-30 10710051 countries:EnglandWales 2021-07-01 2022-06-30 10710051 2021-06-30 10710051 bus:Director1 1 2021-06-30 10710051 core:CostValuation 2021-06-30 10710051 core:OfficeEquipment 2021-06-30 10710051 2020-07-01 2021-06-30 10710051 2021-06-30 10710051 bus:Director1 1 2021-06-30 10710051 core:RetainedEarningsAccumulatedLosses 2021-06-30 10710051 core:ShareCapital 2021-06-30 10710051 core:CurrentFinancialInstruments 2021-06-30 10710051 core:CurrentFinancialInstruments core:WithinOneYear 2021-06-30 10710051 core:Non-currentFinancialInstruments core:AfterOneYear 2021-06-30 10710051 core:OfficeEquipment 2021-06-30 10710051 bus:Director1 1 2020-07-01 2021-06-30 10710051 core:Subsidiary1 2020-07-01 2021-06-30 10710051 bus:Director1 1 2020-06-30 iso4217:GBP xbrli:pure

Registration number: 10710051

Clark Pharma Limited

Filleted Annual Report and Unaudited Financial Statements

for the Year Ended 30 June 2022

 

Clark Pharma Limited

Contents

Company Information

1

Statement of Financial Position

2 to 3

Notes to the Unaudited Financial Statements

4 to 10

 

Clark Pharma Limited

Company Information

Directors

Mr G Clark

Mrs H Clark

Registered office

Hopes Pharmacy
49 Newbottle Street
Houghton Le Spring
DH4 4AR

Accountants

Azets
1 Massey Road
Thornaby
Stockton-on-Tees
TS17 6DY

 

Clark Pharma Limited

(Registration number: 10710051)
Statement of Financial Position as at 30 June 2022

Note

2022
£

2021
£

Fixed assets

 

Tangible assets

4

455

8

Investment property

5

207,149

207,149

Investments

6

2,685,448

2,685,448

 

2,893,052

2,892,605

Current assets

 

Debtors

7

2,335

383

Cash at bank and in hand

 

9,664

34,677

 

11,999

35,060

Creditors: Amounts falling due within one year

8

(325,305)

(326,851)

Net current liabilities

 

(313,306)

(291,791)

Total assets less current liabilities

 

2,579,746

2,600,814

Creditors: Amounts falling due after more than one year

8

(1,999,334)

(2,175,363)

Provisions for liabilities

(114)

(2)

Net assets

 

580,298

425,449

Capital and reserves

 

Called up share capital

200

200

Profit and loss account

580,098

425,249

Total equity

 

580,298

425,449

For the financial year ending 30 June 2022 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476; and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Income Statement.

 

Clark Pharma Limited

(Registration number: 10710051)
Statement of Financial Position as at 30 June 2022 (continued)

Approved and authorised for issue by the Board on 14 March 2023 and signed on its behalf by:
 

.........................................
Mr G Clark
Director

   
     
 

Clark Pharma Limited

Notes to the Unaudited Financial Statements for the Year Ended 30 June 2022

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is Hopes Pharmacy, 49 Newbottle Street, Houghton Le Spring, DH4 4AR.England

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

These financial statements are prepared in sterling which is the functional currency of the entity.

Group accounts not prepared

In the opinion of the directors, the company and its subsidiary undertaking comprise a small group. The company has therefore taken advantage of the exemption provided by Section 398 of the Companies Act 2006 not to prepare group accounts.

Going concern

At the year end the company reported net current liabilities totalling £313,306. However, liabilities includes £124,800 owed to the directors and £16,800 owed to group undertakings. The directors of the company have indicated their willingness to finance any shortages in the company's day to day finances and for such an arrangement to continue for a period of not less than one year from the date the financial statements were approved.

The company meets its day to day working capital requirements through shareholder and external borrowings.

The directors have a reasonable expectation that the company has adequate resources to continue in operational existence for a period of at least 12 months from the date of signing these financial statements. The company therefore continues to adopt the going concern basis in preparing its financial statements.

 

Clark Pharma Limited

Notes to the Unaudited Financial Statements for the Year Ended 30 June 2022 (continued)

2

Accounting policies (continued)

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Tax

The tax expense for the period comprises current and deferred tax. Tax is recognised in profit or loss, except that a charge attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Deferred tax is recognised in respect of all timing differences between taxable profits and profits reported in the financial statements. Unrelieved tax losses and other deferred tax assets are recognised when it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference.

Tangible assets

Tangible assets are stated in the statement of financial position at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

 

Asset class

Depreciation method and rate

 

Office equipment

25% straight line

Investment property

Investment property is carried at fair value, derived from the current market prices for comparable real estate determined annually by external valuers. The valuers use observable market prices, adjusted if necessary for any difference in the nature, location or condition of the specific asset. Changes in fair value are recognised in profit or loss.

 

Clark Pharma Limited

Notes to the Unaudited Financial Statements for the Year Ended 30 June 2022 (continued)

2

Accounting policies (continued)

Business combinations

Business combinations are accounted for using the purchase method. The consideration for each acquisition is measured at the aggregate of the fair values at acquisition date of assets given, liabilities incurred or assumed, and equity instruments issued by the group in exchange for control of the acquired, plus any costs directly attributable to the business combination. When a business combination agreement provides for an adjustment to the cost of the combination contingent on future events, the group includes the estimated amount of that adjustment in the cost of the combination at the acquisition date if the adjustment is probable and can be measured reliably.

Investments

Investments in equity shares which are publicly traded or where the fair value can be measured reliably are initially measured at fair value, with changes in fair value recognised in profit or loss. Investments in equity shares which are not publicly traded and where fair value cannot be measured reliably are measured at cost less impairment. Interest income on debt securities, where applicable, is recognised in income using the effective interest method. Dividends on equity securities are recognised in income when receivable.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Borrowings

Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the income statement over the period of the relevant borrowing.

Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.

Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

 

Clark Pharma Limited

Notes to the Unaudited Financial Statements for the Year Ended 30 June 2022 (continued)

2

Accounting policies (continued)

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

3

Staff numbers

The average number of persons employed by the company (including directors) during the year, was 0 (2021 - 0).

4

Tangible assets

Office equipment
£

Cost or valuation

At 1 July 2021

370

Additions

577

Disposals

(370)

At 30 June 2022

577

Depreciation

At 1 July 2021

362

Charge for the year

130

Eliminated on disposal

(370)

At 30 June 2022

122

Carrying amount

At 30 June 2022

455

At 30 June 2021

8

5

Investment properties

2022
£

At 1 July

207,149

At 30 June

207,149

In the opinion of the directors there has been no material movements in the fair value of the company's investment properties during the year.

There has been no valuation of investment property by an independent valuer.

 

Clark Pharma Limited

Notes to the Unaudited Financial Statements for the Year Ended 30 June 2022 (continued)

6

Investments

2022
£

2021
£

Investments in subsidiaries

2,685,448

2,685,448

Subsidiaries

£

Cost or valuation

At 1 July 2021

2,685,448

Provision

Carrying amount

At 30 June 2022

2,685,448

At 30 June 2021

2,685,448

Details of undertakings

Details of the investments (including principal place of business of unincorporated entities) in which the company holds 20% or more of the nominal value of any class of share capital are as follows:

Undertaking

Registered office

Holding

Proportion of voting rights and shares held

     

2022

2021

Subsidiary undertakings

Frank Jones (Chemist) Limited

Hopes Pharmacy, 49 Newbottle Street, Houghton Le Spring, DH4 4AR.

Ordinary shares

100%

100%

 

     

7

Debtors

2022
£

2021
£

Prepayments

2,335

383

2,335

383

 

Clark Pharma Limited

Notes to the Unaudited Financial Statements for the Year Ended 30 June 2022 (continued)

8

Creditors

Creditors: amounts falling due within one year

2022
£

2021
£

Due within one year

Bank loans

125,470

124,003

Amounts owed to group undertakings

16,800

27,000

Taxation and social security

9,700

12,850

Accruals and deferred income

10,610

6,763

Corporation tax liability

37,925

31,435

Directors loan accounts

124,800

124,800

325,305

326,851

Creditors: amounts falling due after more than one year

2022
£

2021
£

Due after one year

Bank loans

674,334

850,363

Other non-current financial liabilities

1,325,000

1,325,000

1,999,334

2,175,363

-

-

Creditors falling due after more than one year includes £1,325,000 (2021: £1,325,000) convertible loan notes bearing interest at a rate of 1.75% & 2.50% above the Bank of England Base Rate.

 

Clark Pharma Limited

Notes to the Unaudited Financial Statements for the Year Ended 30 June 2022 (continued)

9

Related party transactions

Transactions with directors

2022

At 1 July 2021
£

At 30 June 2022
£

Mr G Clark

Directors loan account

(124,800)

(124,800)

     
   

 

2021

At 1 July 2020
£

At 30 June 2021
£

Mr G Clark

Directors loan account

(124,800)

(124,800)

     
   

 

Summary of transactions with all subsidiaries

During the period, the company made management charges totalling £240,000 (2021: £206,667) to a subsidiary undertaking.
 

10

Non adjusting events after the financial period

Creditors falling due after more than one year includes £1,325,000 (2021: £1,325,000) of convertible loan notes bearing interest at a rate of 1.75% and 2.50% above the Bank of England Base Rate.

The loan note creditor was partially settled post year end for £963,000 with a further £250,000 deferred consideration contractually agreed totalling £1,213,000.